Payer Coverage Decisions Shape Access to Myasthenia Gravis Therapies

Key Takeaways

• Coverage decisions for emerging myasthenia gravis therapies depend on administration route, infrastructure needs, and total cost of care—not just drug price.
• Reliance on single metrics such as Myasthenia Gravis Activities of Daily Living (MG-ADL) scores may overlook meaningful clinical outcomes like hospitalization prevention or respiratory stability.
• Flexible, patient-centered payer models are needed to address disease heterogeneity and evolving treatment response over time.

Coverage design is emerging as a critical determinant of patient access to new myasthenia gravis therapies, according to insights from Amanda L. Hernandez, MD, PhD. In a recent interview, Dr Hernandez emphasized that payer decisions extend beyond cost considerations to include administration logistics, infrastructure requirements, and real-world patient needs, particularly as novel immunotherapies and bispecific treatments enter the market.

Coverage Drivers for Emerging Myasthenia Gravis Therapies

Dr Hernandez highlighted that coverage decisions for newer immunotherapies, including investigational bispecific approaches, are shaped by a combination of clinical, economic, and operational factors. Route of administration plays a central role. Therapies delivered via prefilled syringes or auto-injectors for at-home use may reduce overall costs compared with infusion-based treatments requiring intravenous access, nursing staff, and facility fees.

However, more complex modalities, such as chimeric antigen receptor (CAR) T-cell therapies under exploration in myasthenia gravis, introduce substantial infrastructure demands. These therapies require coordinated care teams and specialized facilities, significantly increasing resource utilization. “Coverage isn’t just about how expensive a therapy is,” said Dr Hernandez, noting the interplay between cost, logistics, and payer structures.

Current payer frameworks often rely on the MG-ADL score to determine eligibility and continuation of therapy. While widely used, Dr Hernandez described this approach as incomplete. She noted that prior authorization submissions typically include clinic notes and MG-ADL documentation, but these may not fully capture patient progress or treatment benefit.

Importantly, she emphasized that treatment decisions should consider broader clinical context, including prior therapies, contraindications, and combination strategies. Outcomes such as reduced hospitalizations, preserved swallowing or respiratory function, and prevention of myasthenic crisis are critical but may not be reflected in standardized scoring thresholds.

Implications for Payer Policy and Patient Access in Myasthenia Gravis

For payers and managed care stakeholders, these insights underscore the limitations of rigid, algorithm-based coverage policies in a highly heterogeneous disease like myasthenia gravis. Patients vary widely in antibody subtype, disease severity, immunopathophysiology, and treatment tolerance, making individualized care essential.

Restrictive step therapy requirements may delay access to optimal treatments, particularly when patients are required to “fail first” before receiving newer options. Dr Hernandez suggested that such policies may not align with patient-centered care, especially as the therapeutic landscape expands.

Additionally, logistical considerations—such as venous access challenges—can influence treatment suitability. For some patients, injectable therapies may be preferable to avoid invasive procedures like port placement, even if cost structures differ. This highlights the need for payer models that account for both clinical and practical realities.

Flexible coverage frameworks that allow therapy adjustments over time are also critical. Myasthenia gravis is a dynamic condition, and treatment efficacy may change as the disease evolves. Policies that enable adaptation can better support long-term outcomes and reduce complications.

Clinician Perspective on Limitations of Current Coverage Models

“Coverage decisions should look beyond a single number,” said Dr Hernandez. “They should consider the patient’s clinical history, prior therapies, combination strategies, contraindications, and overall trajectory.” She added that meaningful outcomes extend beyond MG-ADL improvement, emphasizing the importance of preventing hospitalizations and preserving critical functions such as swallowing and respiration.

Hernandez also cautioned against oversimplified treatment algorithms, noting that autoimmune disease management often requires nuanced, multifactor decision-making rather than linear pathways.

Future Directions for Flexible, Patient-Centered Coverage Models

As new therapies reshape the myasthenia gravis treatment landscape, payer policies will play a pivotal role in determining access. Experts call for more flexible, comprehensive coverage models that reflect disease complexity, prioritize meaningful outcomes, and support individualized patient care.

Reference

Interview with Amanda L. Hernandez, MD, PhD. First Report Managed Care. March 12, 2026.